10.01.2023 - WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today . Seite 1
WATERTOWN, Mass., Jan. 04, 2023 Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein. | January 4, 2023
WATERTOWN, Mass., Nov. 03, 2022 Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader. | November 3, 2022
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Kymera Therapeutics (KYMR) Granted FDA Orphan Drug Designation for KT-333 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced .
Kymera Therapeutics (KYMR) Announces $150 Million Private Placement of Common Stock, Warrants streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.